目的对癌症患者预立医疗照护计划相关文献进行范围审查,为临床开展针对性干预措施提供参考依据。方法以范围综述方法学为指导,计算机检索中国知网、万方、PubMed、Web of Science等数据库,检索时限为建库至2024年4月。结果共纳入22篇文...目的对癌症患者预立医疗照护计划相关文献进行范围审查,为临床开展针对性干预措施提供参考依据。方法以范围综述方法学为指导,计算机检索中国知网、万方、PubMed、Web of Science等数据库,检索时限为建库至2024年4月。结果共纳入22篇文献,9项研究示,癌症患者预立医疗照护计划参与率为22.4%~82.2%,11项研究调查其接受度、准备度及影响因素,2项研究探讨了干预模式。结论癌症患者预立医疗照护计划参与率偏低,主要受人口学因素、疾病相关因素、社会及心理等因素的影响,且其与临床决策关系的结论不一致,现有干预措施较为局限,未来研究可从各因素作为切入点,构建符合我国文化背景的预立医疗照护计划推广模式。展开更多
Dear Editor,Chimeric antigen receptor modifed T(CAR-T)cell therapy has shown potent antitumor activity against relapsed and refractory hematological malignancies.However,its efficacy in solid tumors is limited,partly ...Dear Editor,Chimeric antigen receptor modifed T(CAR-T)cell therapy has shown potent antitumor activity against relapsed and refractory hematological malignancies.However,its efficacy in solid tumors is limited,partly because of the inhibition of PD-L1/PD-1 signaling on CAR-T cells in solid tumors.Further optimizations of CAR-T cells by disrupting PD-1 signaling have improved the anti-tumor efficacy of CAR-T cells.2 Here,we report an alternative approach that sensitizes tumor cells by interferon(IFN)-Y,but without modifying T cells;this strategy surmounts PD-1 inhibition and markedly enhances CAR-T anti-tumor activities in vitro and in vivo.展开更多
文摘目的对癌症患者预立医疗照护计划相关文献进行范围审查,为临床开展针对性干预措施提供参考依据。方法以范围综述方法学为指导,计算机检索中国知网、万方、PubMed、Web of Science等数据库,检索时限为建库至2024年4月。结果共纳入22篇文献,9项研究示,癌症患者预立医疗照护计划参与率为22.4%~82.2%,11项研究调查其接受度、准备度及影响因素,2项研究探讨了干预模式。结论癌症患者预立医疗照护计划参与率偏低,主要受人口学因素、疾病相关因素、社会及心理等因素的影响,且其与临床决策关系的结论不一致,现有干预措施较为局限,未来研究可从各因素作为切入点,构建符合我国文化背景的预立医疗照护计划推广模式。
基金This study was supported by National Science and Technology Major Project 2018ZX09733001-004-003National Natural Science Foundation of China 817726051.3.5 project for disciplines of excellence,West China Hospital,Sichuan University(ZYJC18008).
文摘Dear Editor,Chimeric antigen receptor modifed T(CAR-T)cell therapy has shown potent antitumor activity against relapsed and refractory hematological malignancies.However,its efficacy in solid tumors is limited,partly because of the inhibition of PD-L1/PD-1 signaling on CAR-T cells in solid tumors.Further optimizations of CAR-T cells by disrupting PD-1 signaling have improved the anti-tumor efficacy of CAR-T cells.2 Here,we report an alternative approach that sensitizes tumor cells by interferon(IFN)-Y,but without modifying T cells;this strategy surmounts PD-1 inhibition and markedly enhances CAR-T anti-tumor activities in vitro and in vivo.
